Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects (ANRS 143)
An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001)
Sponsor: ANRS, Emerging Infectious Diseases
This PHASE3 trial investigates HIV Infections and is currently completed. ANRS, Emerging Infectious Diseases leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ANRS, Emerging Infectious Diseases
- NEAT - European AIDS Treatment Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Amsterdam, Netherlands , Antwerp, Belgium , Arnhem, Netherlands , Athens, Greece , Barcelona, Spain , Berlin, Germany , Bonn, Germany , Bordeaux, France , Bournemouth, United Kingdom and 40 more locations